About Cipher Pharmaceuticals (NASDAQ:CPHR)
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA. Its products treat indications, such as severe nodular acne, recurrent herpes labialis, nail dystrophy, dermal ulcers, mild/moderate onychomycosis, acne, dry skin, keratosis, hyperpigmentation, hyperkeratotic actinic keratosis and high cholesterol. Its pipeline of late-stage products includes DERMADEXIN, BETEFLAM PATCH, SITAVIG, PRURIDEXIN, OZENOXACIN, CF101 for plaque psoriasis, CF101 for rheumatoid arthritis, ASF-1096 and NANOLIPOLEE-007. It operates in Canada and the United States.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Other
- Sub-Industry: N/A
- Symbol: NASDAQ:CPHR
- CUSIP: N/A
- Web: www.cipherpharma.com/
- 50 Day Moving Avg: $3.74
- 200 Day Moving Avg: $3.18
- 52 Week Range: $2.55 - $4.22
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 149.50
- P/E Growth: 0.00
- Net Margins: -64.97%
- Return on Equity: -9.83%
- Return on Assets: -4.40%
- Debt-to-Equity Ratio: 1.22%
- Current Ratio: 2.59%
- Quick Ratio: 2.50%
- Average Volume: 914 shs.
- Beta: 1.39
Frequently Asked Questions for Cipher Pharmaceuticals (NASDAQ:CPHR)
What is Cipher Pharmaceuticals' stock symbol?
Cipher Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPHR."
How were Cipher Pharmaceuticals' earnings last quarter?
Cipher Pharmaceuticals Inc (NASDAQ:CPHR) posted its earnings results on Thursday, May, 5th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.04) by $0.06. The business earned $9.10 million during the quarter, compared to analyst estimates of $10.87 million. Cipher Pharmaceuticals had a negative net margin of 64.97% and a negative return on equity of 9.83%. View Cipher Pharmaceuticals' Earnings History.
Where is Cipher Pharmaceuticals' stock going? Where will Cipher Pharmaceuticals' stock price be in 2017?
1 brokers have issued 12-month target prices for Cipher Pharmaceuticals' shares. Their predictions range from $3.50 to $3.50. On average, they anticipate Cipher Pharmaceuticals' share price to reach $3.50 in the next twelve months. View Analyst Ratings for Cipher Pharmaceuticals.
Who are some of Cipher Pharmaceuticals' key competitors?
Some companies that are related to Cipher Pharmaceuticals include Johnson & Johnson (JNJ), Pfizer (PFE), Roche Holding (RHHBY), Novartis AG (NVS), UnitedHealth Group Incorporated (UNH), Merck & Company (MRK), AbbVie (ABBV), Amgen (AMGN), Novo Nordisk A/S (NVO), Sanofi (SNY), Bayer AG (BAYRY), Celgene Corporation (CELG), Medtronic PLC (MDT), Gilead Sciences (GILD), Bristol-Myers Squibb Company (BMY), GlaxoSmithKline PLC (GSK), Abbott Laboratories (ABT) and Eli Lilly and Company (LLY).
How do I buy Cipher Pharmaceuticals stock?
Shares of Cipher Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cipher Pharmaceuticals' stock price today?
MarketBeat Community Rating for Cipher Pharmaceuticals (NASDAQ CPHR)MarketBeat's community ratings are surveys of what our community members think about Cipher Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Cipher Pharmaceuticals stock can currently be purchased for approximately $2.99.
Earnings History for Cipher Pharmaceuticals (NASDAQ:CPHR)Earnings History by Quarter for Cipher Pharmaceuticals (NASDAQ CPHR)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/11/2016||Q316||($0.10)||($0.08)||$10.42 million||$9.30 million||View||N/A|
|5/5/2016||Q116||($0.04)||($0.10)||$10.87 million||$9.10 million||View||N/A|
|11/4/2015||Q3 2015||$0.07||($0.04)||$12.50 million||$8.46 million||View||N/A|
|8/14/2015||Q2 2015||$0.02||$0.01||$11.50 million||$8.84 million||View||N/A|
|5/13/2015||Q115||$0.17||$0.10||$7.88 million||$9.18 million||View||N/A|
|2/25/2015||Q4 2014||$0.12||$0.11||$6.72 million||View||N/A|
Earnings Estimates for Cipher Pharmaceuticals (NASDAQ:CPHR)
2017 EPS Consensus Estimate: $0.04
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Cipher Pharmaceuticals (NASDAQ:CPHR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Cipher Pharmaceuticals (NASDAQ:CPHR)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Cipher Pharmaceuticals (NASDAQ:CPHR)
Latest Headlines for Cipher Pharmaceuticals (NASDAQ:CPHR)
Cipher Pharmaceuticals (CPHR) Chart for Friday, October, 20, 2017